文献速递免疫规划传染病防控与疫情报告

mRNA疫苗相比Sputnik V病毒载体疫苗在初治和康复人群中诱导持续更优的体液免疫应答

Sustained superior humoral immune responses of mRNA vaccines compared to Sputnik V viral vector COVID-19 vaccines in naïve and convalescent populations.
PubMed 文献 · Vaccine · 2025-12-02

该研究比较了BNT162b2/mRNA-1273(mRNA疫苗)与Sputnik V(腺病毒载体疫苗)在多个时间点的体液免疫应答。结果显示,mRNA疫苗在初治人群中诱导更高的结合抗体(p < 0.001)和中和抗体(p < 0.001)应答,在康复人群中结合抗体应答也更高(p < 0.05)。两种平台的抗体衰减动力学相似(半衰期约5个月),但mRNA疫苗在接种后6个月内保持持续优势。

要点

  • mRNA疫苗在初治人群中结合抗体和中和抗体应答均显著高于Sputnik V。
  • 在康复人群中,mRNA疫苗的结合抗体应答也显著高于Sputnik V。
  • 两种疫苗抗体半衰期均约5个月,但mRNA疫苗优势持续至接种后6个月。

核心结论

  • mRNA疫苗接种相比腺病毒载体疫苗提供显著更优且持续的抗体应答,对长期保护策略有重要意义。

研究设计与样本

  • 研究纳入48名初治和24名康复期参与者,比较mRNA疫苗(BNT162b2/mRNA-1273)与Sputnik V(腺病毒载体疫苗)的体液免疫应答。
  • 使用ELISA检测抗原始株(WT)刺突结合抗体,使用活SARS-CoV-2 WA.1株微量中和试验检测中和抗体。
  • 血清采集于基础免疫前后,mRNA组28人,Sputnik V组44人。

主要发现

  • mRNA疫苗诱导的结合抗体应答在初治人群中显著高于Sputnik V(p < 0.001),在康复人群中亦显著更高(p < 0.05)。
  • mRNA疫苗诱导的中和抗体应答在初治人群中显著高于Sputnik V(p < 0.001)。
  • 两种疫苗平台的抗体衰减动力学相似,半衰期约5个月,mRNA疫苗的优越性持续至接种后6个月。

关键数值与推荐

  • 结合抗体应答:mRNA疫苗 vs Sputnik V,初治人群 p < 0.001,康复人群 p < 0.05。
  • 中和抗体应答:mRNA疫苗 vs Sputnik V,初治人群 p < 0.001。
  • 抗体半衰期约5个月,mRNA疫苗优势持续至接种后6个月。

临床怎么用

  • 在制定长期COVID-19疫苗策略时,可优先考虑mRNA疫苗以诱导更强且持续的体液免疫应答。
  • 对于初治和康复人群,mRNA疫苗均显示优于腺病毒载体疫苗的抗体应答,可指导疫苗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The choice of vaccine platform fundamentally influences the magnitude and durability of antibody responses against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). We compared humoral immune responses between BNT162b2/mRNA-1273 (mRNA) and Sputnik V (adenoviral vector) vaccines across multiple timepoints. METHODS: Anti-ancestral (WT) spike binding antibodies were measured by enzyme-linked immunosorbent assay (ELISA) and neutralizing antibodies by microneutralization assay using live SARS-CoV-2 WA.1 strain. Sera from 48 naïve and 24 convalescent study participants were collected prior and after the primary immunization (mRNA: 28; Sputnik V: 44). RESULTS: mRNA vaccines elicited higher binding antibody responses (p < 0.001 in naïve, p < 0.05 in convalescent participants) and neutralizing antibody responses (p < 0.001 in naïve participants) compared to Sputnik V. Antibody decay kinetics were similar between platforms (half-life ∼5 months), with mRNA vaccines maintaining sustained superiority through 6 months post-vaccination. CONCLUSIONS: mRNA vaccination provides markedly superior and sustained antibody responses compared to adenoviral vector vaccine, which is particularly relevant for long-term protection strategies.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Abbad A, Lerman B, Ehrenhaus J, et al. Sustained superior humoral immune responses of mRNA vaccines compared to Sputnik V viral vector COVID-19 vaccines in naïve and convalescent populations. Vaccine. 2025. PMID: 41337980. doi:10.1016/j.vaccine.2025.128018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。